CANSINOBIO Interim Loss Narrows to RMB721,000, Revenue Up 46.1%AASTOCKS News·8 hours ago06185-1.35%688185+8.36%
CanSino Biologics partners with deepGeneAI to develop personalized mRNA cancer vaccinesPUBT·1 day ago, 05:18 AM06185-1.35%688185+8.36%
CANSINOBIO Surges Nearly 25% at Peak After Signing Strategic Cooperation Framework for Joint Development of mRNA Personalized Therapeutic Cancer VaccinesAASTOCKS News·1 day ago, 10:45 PM06185-1.35%688185+8.36%
Hong Kong stock movement: CANSINOBIO rises nearly 13%: partners with DepoMed to promote mRNA tumor vaccine, strong expectations for valuation recoveryHK Stock Alerts·1 day ago, 08:33 PM06185-1.35%
CanSinoBIO, deepGeneAI sign framework pact to develop personalized mRNA cancer vaccinesPUBT·2 days ago, 04:01 AM06185-1.35%688185+8.36%
CANSINOBIO Tetanus Vaccine New Drug Application ApprovedAASTOCKS News·Aug 20 at 08:21 AM06185-1.35%688185+8.36%
CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDAPUBT·Aug 20 at 05:43 AM06185-1.35%688185+8.36%
CANSINOBIO Shares Surge on Moderna Positive Phase III mRNA Cancer Vaccine Trial ResultsAASTOCKS News·Aug 20 at 01:51 AMMRNA-4.39%MRNX-8.65%
CanSinoBIO spotlights meningococcal vaccine strategy at Asian pediatric infectious diseases congressPUBT·Aug 18 at 08:11 AM06185-1.35%688185+8.36%
CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine PipelineAsian Corporate Newswire·Aug 16 at 07:24 AM06185-1.35%688185+8.36%
